Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Recent findings in cancer vaccines described by R. Yanez and colleagues
June 25th, 2008
According to a study from Madrid, Spain, "A specific immune response against the individual idiotypic determinants of clonal immunoglobulins can be elicited in patients with B-cell malignancies." "We analyze the clinical outcome and the presence of tumor cells in the blood of 8 patients with follicular lymphoma, vaccinated with autologous idiotype protein from their lymphoma cells. After a median follow-up of 90 months (range: 54 to 128), all patients, except 1, remain in complete clinical remission and 5 are in complete molecular remission," wrote R. Yanez and colleagues. The researchers concluded: "Our results suggest that idiotype vaccination...
Source: Vaccine Weekly (2008-06-25)
|
